Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer



    - Phase 3 study has demonstrated that Induction Chemotherapy prior to
ChemoRadiotherapy significantly increased time-to-treatment failure in
comparison to standard ChemoRadiotherapy alone -

    MADRID, May 30 /PRNewswire/ -- The Spanish Head and Neck Cancer
Cooperative Group (TTCC) announced today that Induction Chemotherapy (IC)
delivered prior to standard ChemoRadiotherapy (CRT), a treatment paradigm
defined as sequential therapy, compared to upfront CRT alone, significantly
prolonged Time-to-Treatment Failure (TTF) for patients with unresectable
Locally Advanced Head and Neck Cancer (LAHNC). The endpoint of
Time-to-Treatment Failure was defined as a composite of time-to-disease
progression, -to-surgery or other cancer-related treatments, -to-drop-out due
to an adverse event, and to death from any cause.

    Final results (abstract #6009) from the Phase 3 randomized study were
presented by Prof. Ricardo Hitt, of the University Hospital 12 de Octubre,
Madrid, in an oral presentation at the 2009 annual meeting of the American
Society of Clinical Oncology (ASCO). The results of this study have also been
selected for inclusion in the Best of ASCO(R) program. The Best of ASCO(R) is
an educational initiative that condenses highlights from ASCO's Annual
Meeting, with the objective of increasing global access to cutting-edge
science that is relevant and significant in oncology today.

    This study enrolled 439 patients with Locally Advanced Head and Neck
Cancer with good performance status, who were randomly assigned to receive
standard CRT (cisplatin and fractionated radiation) versus the same treatment
preceded by IC, which consisted of cisplatin plus 5-fluorouracil (5-FU) with
or without Taxotere(R) (docetaxel) Injection Concentrate. The study was
designed to compare the results of those patients who received IC prior to CRT
(sequential therapy) and patients who received CRT alone.

    The sequential therapy of adding IC to CRT improved Time-to-Treatment
Failure (TTF) from 5.0 months to 12.5 months (p< 0.0001), a 7.5 month
increase. Furthermore, a secondary endpoint of loco-regional control, was
observed in 61.5% of the patients treated with the sequential strategy
(IC+CRT) compared to 44.5% of those patients treated with CRT alone (p=0.002).

    The most frequent severe (grade 3-4) adverse reactions were stomatitis
(44% for IC+CRT vs. 31% for CRT) and febrile neutropenia (10% for IC+CRT vs.
1% for CRT). Other adverse events included neutropenia and asthenia.

    "These study results illustrate that this complex disease deserves a
rational and comprehensive management strategy to overcome its pathologic
mechanism and the inherent possibility of failure of clinical control," said
Prof. Ricardo Hitt, MD, PhD, the study principal investigator, from Medical
Oncology Service of the University Hospital 12 de Octubre, Madrid, Spain.

    Every year more than 640,000 people worldwide are diagnosed with head and
neck cancer, and an estimated more than 350,000 will die from the disease.
Head and neck cancer is a group of tumors that mostly arise in the cells that
line the mucosal surfaces, giving rise to squamous cell carcinoma in the head
and neck area, such as the mouth, tongue, tonsils, voice box and throat.

    "This trial showed that adding Induction Chemotherapy to
ChemoRadiotherapy increased failure-free survival while significantly
increasing local control in patients with advanced unresectable head and neck
cancer," said Fadlo Khuri, MD, Professor and Roberto Goizueta Chair of
Hematology and Medical Oncology at Emory University, Atlanta, GA, USA.  Dr.
Khuri, a renowned head and neck cancer expert, also added: "These data may
help define and clarify standard approaches to the treatment of patients with
advanced unresectable disease."
    

    About the Spanish Head and Neck Cancer Cooperative Group, TTCC
    
    Grupo Espanol de Tratamiento de Tumores de Cabeza y Cuello (TTCC) is a
Spanish non-profit scientific cooperative group fully devoted to head and neck
cancer. The group is comprised of medical oncologists, who belong to the
Spanish Society of Medical Oncology (SEOM) as well as of other health
professionals related to head and neck cancer research and treatment. The main
Spanish Head and Neck Cancer Cooperative Group objectives are to promote
basic, epidemiological and clinical research, and to provide education to
doctors and patients and dissemination of information in the field of head and
neck cancer to the Spanish general population.


    
    Contact TTCC:
    Pr. Ricardo Hitt: + 34 629 26 28 33
    

    
    Tara Dimilia: 908-884-7024


    




For further information:

For further information: Professor Ricardo Hitt, +34-629-26-28-33, or
Tara Dimilia, +1-908-884-7024, both for Spanish Head and Neck Cancer
Cooperative Group Web Site: http://www.sanofi-aventis.us                
http://www.sanofi-aventis.com

Organization Profile

SPANISH HEAD AND NECK CANCER COOPERATIVE GROUP

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890